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The recently published 2016 World Health Organization (WHO) Classification of Tumors of the Urinary System and
Male Genital Organs stems from the accumulated knowledge and data collected during the last 12 years, since the
previous edition of the WHO “blue book” 2004.
The major changes in prostate pathology include the introduction of a novel grading system for prostate cancer
(Grade Groups/International Society of Urological Pathology (ISUP) grades 1–5), the recognition of intraductal
carcinoma as a new entity, and the terminological changes regarding the neuroendocrine prostatic neoplasms.
In bladder and urothelial tract, within the spectrum of flat and non-invasive lesions, a newly introduced term
“urothelial proliferation of uncertain malignant potential” replaced the term “urothelial hyperplasia”, and the term
“urothelial dysplasia” was better defined. A category of “invasive urothelial carcinoma with divergent differentiation” was
introduced for tumors showing a component of “usual type” urothelial carcinoma combined with other morphologies.
A new WHO/ISUP renal tumor grading system was recommended (Grade 1–4). The definition of renal papillary
adenoma was modified and expanded to include papillary neoplasms measuring up to 1.5 cm. Several new
epithelial renal tumors were recognized as new entities including: hereditary leiomyomatosis and renal cell
carcinoma (RCC) syndrome–associated RCC, succinate dehydrogenase–deficient RCC, tubulocystic RCC, acquired
cystic disease–associated RCC, and clear cell papillary RCC.
In testis pathology, intratubular proliferations of testicular germ cell tumors were renamed as “germ cell neoplasia
in-situ” (GCNIS), and the testicular neoplasms were divided into two main groups: derived from or unrelated to GCNIS.
A major change in penile pathology was the introduction of a new classification of penile squamous cell carcinoma,
based on the presence of human papillomavirus (HPV), which characterizes penile tumor subtypes as HPV-related or
non-HPV-related. A similar distinction was introduced for the preneoplastic penile intraepithelial precursor lesion (PeIN)
into non-HPV related (differentiated PeIN) and HPV-related types (undifferentiated PeIN). In this review, we provide a
summary and highlight the changes in the genitourinary pathology introduced by the 2016 WHO blue book, and we
also discuss some recent developments that may impact the practice of genitourinary pathology in the near future.
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The recently published 2016 World Health Organization
(WHO) Classification of Tumors of the Urinary System
and Male Genital Organs stems from the accumulated
knowledge and data collected during the last 12 years,
since the previous edition of the WHO “blue book”
2004. In this review, we provide a summary of the high-
lights and the changes in genitourinary pathology intro-
duced by the 2016 WHO blue book, and we discuss
some recent developments that may impact the practice
of genitourinary pathology in the near future.
Prostate
Novel prostate adenocarcinoma grading
Over the last half a century, the Gleason grading system
has been validated as a fundamental prognostic factor
for patient outcome, on biopsy and on radical prostatec-
tomy (RP), including biochemical failure, local recur-
rence and lymph node or distant metastasis. However,
over the last two decades or so, many changes took
place, including the introduction of a practice of thin-
needle prostate biopsies, first as sextant, and then as sys-
tematic and extended prostate biopsies with site specific
submission, with introduction and widespread use of
immunohistochemistry (IHC), recognition of variants of
adenocarcinoma, and the prognostic significance of cer-
tain morphologic patterns. These developments led to
grading changes by the ISUP in 2005 (ISUP Modified
Gleason System 2005) [1] and in 2014 (ISUP Consensus
Conference on Gleason Grading 2014) [2]. The latest
modifications from 2014 were incorporated in the WHO
2016 classification of prostate adenocarcinoma, which
establishes a novel grading system based on stratification
of the Gleason scores in Grade Groups/ISUP Grades 1
to 5, corresponding to Gleason scores ≤6, 3 + 4, 4 + 3, 8
(4 + 4, 3 + 5, 5 + 3) and ≥9 [3]. The Grade Group 1
(Gleason scores ≤6) is the lowest recommended grade as
Gleason scores 2–5 are rarely used in the current prac-
tice and essentially pertain to the large majority of cases
of Gleason score 6. It currently includes well differenti-
ated and slow growing tumors that virtually have no po-
tential of metastasizing and in many circumstances can
be handled by active surveillance. It is currently recom-
mended that this new grading system be reported in
conjunction with the 2005 ISUP modified Gleason system.
A recent study has validated the prognostic significance of
the new grading system in a large multi- institutional co-
hort treated by radical prostatectomy and radiotherapy,
using the biochemical recurrence as an outcome measure
[4]. In another recent study from the UK, there was a
strong correlation between the five grade groups and
prostate cancer death [5].
The Consensus meeting of ISUP 2014 also added the
following recommendations which are included in the2016 WHO blue book and are confirmed by some more
recent data [2, 4]:
– Glomeruloid glands and all cribriform gland
morphologies should be assigned Gleason pattern 4.
– Mucinous carcinoma should be graded on the basis
of its background growth pattern instead of being
classified automatically as pattern 4.
Cribriform morphology has been associated with up-
grading at RP when assigned in needle biopsies [6] and
with cancer progression in RP specimens [7, 8], and it
should be documented in needle biopsies when present.
The current general rules in assigning and reporting
Gleason scores in needle biopsy and RP mirror the
recommendations from the 2005 ISUP consensus [1].
Although it has been previously recommended to quan-
tify the amount of high grade carcinoma patterns 4 and
5 in needle biopsies and RP specimens, the reporting of
percent pattern 4 is inconsistently done in clinical prac-
tice. In RP specimens, the amount of high grade com-
ponent (Gleason patterns 4/5) has been previously
confirmed to be an important predictor of survival [9].
However, it is now recommended to quantify the per-
centage pattern 4 in Gleason score 7 (3 + 4 or 4 + 3),
when this is the highest grade in a needle biopsy or RP
specimens. For example, a low percentage of pattern 4
in cases considered for active surveillance may influence a
clinical decision for these patients to be selected for con-
servative management [10].
Intraductal carcinoma
Intraductal carcinoma has been recognized formally as a
new entity in the 2016 WHO classifications, although
this term and its morphology have been described pre-
viously [11]. It represents an intraepithelial spread or
in-situ proliferation of acinar and ductal carcinoma,
likely representing a late event in prostate cancer pro-
gression. It is defined by intraacinar/intraductal prolife-
ration that may share some morphologic features with
high grade prostatic intraepithelial neoplasia (HGPIN),
but exhibits a much higher degree of architectural and
cytologic atypia. Intraductal carcinoma should not be
assigned a Gleason grade. It is rarelyan isolated finding
in needle biopsy (0.1–0.3%), and most of the cases are
associated with high grade invasive carcinoma both in
needle biopsies and RP. The frequency of intraductal
carcinomas in RP specimens depends on the grade and
the stage of tumors, ranging from 20 to 40% of all RP
cases, while it is much lower in needle biopsies (about
3%). The presence of isolated intraductal carcinoma in
a needle biopsy should be reported with a comment de-
scribing its strong association with high grade and high
volume prostatic carcinoma, which likely was not
Fig. 1 a Intraductal carcinoma of prostate on needle core biopsy demonstrating significant cell atypia and cribriform growth. b Intraductal carcinoma
shows preserved basal cell layer, highlighted by continuous staining for high molecular weight cytokeratin
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invasive carcinoma, a recommendation should be given
for repeat biopsy, prior to definitive therapy,
The distinction between HGPIN, the only currently
recognized form of prostate preneoplastic lesion, and
intraductal carcinoma is crucial. Both show preservation
of the basal cell layers, but intraductal carcinoma shows
more commonly a dense cribriform or solid growth pat-
terns, with frequent central comedonecrosis (Fig. 1a-b).
The differential diagnosis in this setting may also include
a solid growth pattern of invasive urothelial carcinoma.
Another form of intraductal carcinoma demonstrates
loose cribriform and micropapillary morphology, which
should demonstrate high grade cytology with marked
nuclear atypia (nuclei ≥ 6 times higher than normal nuclei,
or adjacent lymphocytes). In difficult cases, a diagnosis of
atypical intraductal or cribriform growth may be used,
with a comment that intraductal carcinoma cannot be
ruled out. The expression of ERG and loss of PTEN in
intraductal carcinoma have been advocated as useful
supplementary tools, but technical difficulties in PTEN
immunostaining currently preclude a recommendation for
its widespread use.
New variants of prostatic adenocarcinoma
Two new variants of prostatic adenocarcinoma were
included in the new blue book. The microcystic variant
is characterized by acini that are 10 times the size of
usual small acinar carcinoma, with rounded profiles and
flat cell lining. The may show bland cytological features
mimicking benign cystic atrophy. The assigned Gleason
pattern is 3. Pleomorphic giant cell variant is exception-
ally rare variant characterized by giant, bizarre, anaplas-
tic cells with pleomorphic nuclei and lacking a spindlecell component. In some patients there is a history of
prior hormonal or radiation therapy. The disease course
is very aggressive.
Variants of neuroendocrine tumors of the prostate
Large cell neuroendocrine carcinoma, which is morpho-
logically identical to its counterpart in the lung, has now
been included in the 2016 WHO Classification of pros-
tate tumors as a new variant [11]. Almost all cases were
associated with hormonal treatment of prostate adeno-
carcinoma. Small cell carcinoma has been renamed small
cell neuroendocrine carcinoma and carcinoid tumor has
been now designated as well differentiated neuroendocrine
tumor of prostate.
Immunophenotype
The novel and useful markers for prostate differentiation
include prostein (P501S), a plasma membrane protein and
NKX3.1, a homeobox-containing transcription factor, both
highly sensitive for prostate adenocarcinoma [12]. These
markers can be particularly useful in poorly differentiated
prostate carcinoma cases demonstrating negative first line
prostate markers, such as prostate-specific antigen (PSA)
and prostate-specific acid phosphatase (PSAP), to sep-
arate them from urothelial carcinoma, for a diagnosis
in a metastatic setting, or in tumors in which PSA and
PSAP were significantly decreased due to androgen
deprivation therapy.
Bladder and urinary tract
Urothelial tumor grading
The new 2016 WHO blue book continued to endorse
the classification of urothelial flat and papillary lesions
proposed initially by ISUP in 1997, and adopted by the
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prised in the literature, which recognized its merits
and advantages regarding the reproducibility and clin-
ical significance when compared to WHO 1971 classi-
fication, which is currently used infrequently [13, 14].
This classification provided uniform grading termin-
ology, based on the observed cytologic and architec-
tural abnormalities, and more specific criteria for
various preneoplastic conditions and grades. It also
eliminated the ambiguous “transitional” grades (grade
1–2, grade 2–3) and maintained the existence of a
category papillary urothelial neoplasm of low malig-
nant potential (PUNLMP), which has a substantial
potential for recurrence, but a very small risk of pro-
gression [15].Urothelial proliferation of uncertain malignant potential
In the diagnostic categories, the novel change is the re-
placement of the term “urothelial hyperplasia” by the
term urothelial proliferation of uncertain malignant
potential (UPUMP). This lesion represents a lesion with
flat thickened urothelium with minimal or no cyto-
logical atypia; undulations are common, but true papil-
lary fronds are lacking. The term is meant to represent
the flat counterpart of the papillary urothelial neoplasm
of low malignant potential (PUNLMP), which continues
to be endorsed. The clinical relevance of UPUMP is not
known, although it is possible that it represents a
“shoulder lesion”, commonly seen adjacent to true papil-
lary neoplasms. This lesion can also be seen de novo, with
uncertain clinical significance.Fig. 2 a Urothelial dysplasia is a flat preneoplastic lesion demonstrating a d
urothelial carcinoma in-situ. b Cytokeratin 20 exhibits diffuse full thickness rea
only umbrella cells are positive (top)Urothelial dysplasia
This is a flat preneoplastic lesion with a degree of cyto-
logic and architectural abnormalities that fall short of
urothelial carcinoma in-situ (CIS) (Fig. 2a-b). It is often
difficult to differentiate urothelial dysplasia from urothe-
lium with reactive atypia or atypia of uncertain signifi-
cance, particularly in settings of prior urothelial carcinoma,
procedures, and use of intravesical therapy. This lesion is
difficult to define precisely by morphology, primarily due
to interobserver variability and lack of data on its relation-
ship for development of subsequent CIS; however, the use
of this diagnostic term is recommended. Strong and diffuse
full thickness urothelial reactivity with cytokeratin 20 on
IHC, as in urothelial CIS, may aid in establishing a diagno-
sis of urothelial dysplasia.Invasive urothelial carcinoma with divergent
differentiation and urothelial carcinoma variants
Invasive urothelial carcinomas demonstrate a broad var-
iety of divergent differentiation, typically in combination
with the “usual type” urothelial carcinoma, in about a
third of the cases. The 2016 WHO blue book advocates
the term infiltrating urothelial carcinoma with divergent
differentiation and recommends that the amount of di-
vergent histologies should be reported as a percentage
[14]. It is believed that divergent differentiation is associ-
ated with poorer outcome, even though it has not been
found to be a consistent independent risk factor in all
studies and, at present, there is no direct relationship of
the amount of divergent histology with the prognosis.
The most common lines of divergent differentiations areegree of cytologic and architectural abnormalities that fall short of
ctivity in dysplastic urothelium (bottom), while in the normal urothelium
Fig. 3 a Glandular differentiation of mucinous type, demonstrating muscle invasion with extravasated mucin and free floating cells, including
cells with signet-ring morphology. b Plasmacytoid carcinoma showing signet-ring cell morphology without extracellular mucin or gland formation.
c Micropapillary carcinoma showing numerous micropapillary and ring formations floating in lacunar spaces. d Nested carcinoma is composed of small
nests with deceptively bland cytology demonstrating extensive invasion into lamina propria
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20%). The novel variants of urothelial carcinoma include
glandular neoplasms of enteric type, morphogically iden-
tical to the colonic counterpart and the mucinous type,
characterized with extravasated mucin and free floating
cells, including cells with signet ring morphology (Fig. 3a).
The typical signet ring cell carcinoma however shows no
association with extracellular mucin or gland formation
and usually coexists with a predominant plasmacytoid
morphology (Fig. 3b). Distinction between enteric type
differentiation and primary colonic adenocarcinoma
can be challenging, because divergent enteric differenti-
ation of urothelial carcinomas is associated with gain of
CDX2 and cytokeratin 20 expression, and loss of GATA3,
p63 and high molecular weight cytokeratin. In this setting,
as recommended by ISUP, the most useful marker is beta-
catenin which shows nuclear reactivity in 90% of colonic
adenocarcinomas and 90% membrane reactivity in over
90% of primary bladder adenocarcinomas or urothelial
carcinomas with glandular differentiation [16]. Micropa-
pillary, plasmacytoid, nested and poorly differentiated var-
iants of urothelial carcinoma are associated with more
aggressive behavior and poor outcome (Fig. 3c-d). Nested,
large nested and microcystic variants of urothelial carcin-
oma are also important because they demonstrate
deceptively bland cytological morphology and may bemisdiagnosed as benign lesions, although they are inher-
ently aggressive. Other morphologies include trophoblastic,
lymphoepithelioma-like, giant cell, lipid-rich, clear cell and
sarcomatoid, which can sometimes appear as variable pat-
terns of divergent differentiation in urothelial carcinoma.
Tumors of Müllerian origin
A new category of bladder neoplasms comprise the tu-
mors of Müllerian origin which originate primarily from
the bladder wall or the adjacent soft tissues, likely from
foci of endometriosis or müllerianosis [14]. It is unlikely
that these tumors are of urothelial origin. They typically
show tubulocystic, papillary or diffuse morphology. The
most common types are clear cell carcinoma and endo-
metrioid carcinoma, both of which share overlapping
morphologic and immunophenotypical features with
their ovarian counterparts.
Tumors arising in a bladder diverticulum
Another new neoplastic category represents the tumors
arising in a bladder diverticulum [14]. About 14% of all
bladder diverticula will harbor a malignant tumor and
these tumors comprise about 1% of all bladder cancers.
About half of the tumors are non-invasive, while the
other half are invasive; all tumors are mostly of usual
urothelial type. Since the diverticula lack the muscularis
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setting differs from others carcinomas of the bladder, as
pT2 stage does not exist.
Neuroendocrine tumors of bladder
Similar to the prostate, small cell carcinoma has been
renamed small cell neuroendocrine carcinoma and car-
cinoid tumor has been named well differentiated neuro-
endocrine tumor of bladder. The entity large cell
neuroendocrine carcinoma, has now also been included
in the 2016 WHO Classification of bladder tumors as a
new variant.
Kidney
Changes pertaining to existing renal tumor types
The ISUP Vancouver consensus conference in 2012 was
the basis for the updates of the 2016 WHO renal tumor
classification [17]. Multilocular cystic renal cell carcino-
ma (RCC) has been renamed multilocular cystic renal
neoplasm of low malignant potential. These are indolent
tumors which resemble low grade clear cell RCC with
extensive cyst formation, but without the expansive
nodules. Although traditionally papillary RCC has been
divided into types 1 and 2, it is becoming apparent that
“type 2 papillary RCC” may not constitute a single entity,
but rather represent a morphology seen in a variety of
neoplasms, including, for example, Xp11 translocation
RCC and collecting duct RCC, as acknowledged in the
2016 WHO renal tumor classification. It is conceivable
that type 2 papillary RCC is an umbrella category com-
prising tumors with similar morphology, but distinct
molecular backgrounds. In addition, there is papillary
RCC with eosinophilic (oncocytic) cytoplasm (oncocytic
papillary RCC variant), which is included in type 2 papillary
RCC in the new classification, till it is better characterized.
The size criterion for papillary adenoma, previously de-
fined as papillary tumor ≤0.5 cm, has been changed and
expanded to include all unencapsulated tumors of lower
grade with papillary or tubular morphology up to 1.5 cm in
size, because they essentially have no metastatic potential.
Finding these types of relatively common tumors in poten-
tial donor kidneys should not be a contraindication for
allograft transplantation. Mixed epithelial and stromal tu-
mors (MEST) has been now been defined to include a
broad spectrum of tumors from almost exclusively cystic at
one end (cystic nephroma), to tumors that are predomin-
antly solid at the other end (classical MEST). In contrast to
adult cystic nephroma, pediatric cystic nephroma repre-
sents a distinct entity characterized by DICER1 mutation.
Xp11 translocation carcinoma has been renamed MiT
family translocation RCC to include not only TFE3
translocation tumors, but also TFEB tumors. Carcino-
ma of the collecting duct of Bellini has been renamed
collecting duct RCC. Carcinoid of the kidney, most ofwhich have poor prognosis, has been renamed well dif-
ferentiated neuroendocrine tumor of kidney, and placed
within the spectrum of renal endocrine tumors, which
include small and large cell neuroendocrine carcinomas
and paragangliomas (extrarenal pheochromocytoma).
New renal tumor entities
Renal cell carcinomas are subtyped on the basis of their
morphologic architectural and cytologic features, ana-
tomic location or the association with specific disease,
molecular alterations or familial syndromes. Many un-
classified RCC in the past can now be correctly diag-
nosed or reclassified using the accumulated data and
knowledge, along with proper molecular testing, which
is increasingly becoming available in selected reference
centers.
Several entities are recognized as new RCC subtypes
in the WHO 2016 blue book [18].
Hereditary leiomyomatosis and renal cell carcinoma (RCC)
syndrome associated-RCC
Hereditary leiomyomatosis and renal cancer syndrome
(HLRCC) is an autosomal dominant disorder characterized
by inherited predisposition to uterine and cutaneous leio-
myomas and renal cell carcinoma. It is characterized by in-
activating germ-line mutation in the fumarate hydratase
(FH) gene, which is located at 1q42.3-q43 and codes for an
enzyme involved in the tricarboxylic acid cycle, which cata-
lyzes and hydrates fumarate to form malate. HLRCC asso-
ciated -RCC are morphologically characterized by frequent
papillary architecture, abundant eosinophilic cytoplasm,
large nuclei and very prominent nucleoli (“cherry-red
nucleoli”) with perinucleolar clearing, that resemble viral
inclusions [19] (Fig. 4a-b). FH deficiency can be demon-
strated by the absence of staining for FH on IHC. Recent
data indicate that the spectrum of so called “FH-deficient
RCC” may be broader and may include tumors with papil-
lary and other morphologies, not currently considered to
fit the strict definition of HLRCC syndrome associated-
RCC [20, 21]. It is important that these tumors are
identified because they show aggressive behavior and
poor outcome and may run in families.
Succinate dehydrogenase-deficient RCC
SDH-deficient renal carcinoma represents a distinct and
rare renal neoplasm, which is defined by loss of IHC
staining for SDHB, which indicates mitochondrial com-
plex II dysfunction [22, 23]. Great majority of SDH-
deficient renal tumors demonstrate typical appearances at
least focally with uniform low-grade cytology, cytoplasmic
vacuoles, eosinophilic or flocculent (not oncocytic) cyto-
plasm, focal cystic change, and solid to lobulated growth
with peripherally entrapped renal tubules (Fig. 4c-d). In
tumors exhibiting low-grade nuclear features, metastasis
Fig. 4 a HLRCC syndrome-associated RCC shows abundant eosinophilic cytoplasm, large nuclei and very prominent nucleoli with perinucleolar halos that
resemble viral inclusions. b FH deficiency can be demonstrated by the lack of staining for FH on immunohistochemistry (only the background stromal cells
are FH positive). c Typical appearances of SDH-deficient RCC with uniform low-grade cytology, cytoplasmic vacuoles, and eosinophilic or flocculent
cytoplasm. d All SDH-deficient RCC show negative staining for SDHB on IHC; note the positive mast cells, which are often seen in the background
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coagulative necrosis or sarcomatoid transformation,
demonstrate potential for metastatic disease, often after
a prolonged period. The patients with these tumors also
have increased risk of developing paragangliomas and
gastrointestinal stromal tumors. Great majority of the
reported cases have been associated with germline mu-
tations of the SDH genes.
Tubulocystic RCC
Tubulocystic RCC is composed of variable-sized cysts,
which provide a spongy cut surface on gross examination.
The key feature is the morphology of variable-sized tu-
bules and cysts which are lined by a single layer of flat or
hobnail cell with prominent nucleoli (ISUP/WHO grade
3) and separated by thin fibrous septa. This is also a rare
tumor, which accounts for less than 1% of all kidney tu-
mors. It shows predilection for male patients. Only a
small minority of reported cases showed metastatic be-
havior. As cytogenetic (trisomy 7 and 17, loss of Y) and
immunoprofile (CK7, CD10, AMACR all positive) simi-
larities have been found with papillary RCC, they may
be related to papillary RCC. Of note, the presence of
tubulocystic morphology admixed with other architec-
tural patterns (or areas of dedifferentiation), argues
strongly against the diagnosis of tubulocystic RCC and
may indicate other tumor type (e.g. FH-deficient RCC).Acquired cystic disease associated RCC
Acquired cystic disease associated RCC typically arises
in end-stage kidneys showing acquired cystic disease,
often after prolonged dialysis. Although this is the most
common subtype of RCC arising in end-stage renal dis-
ease and acquired cystic disease, about 2/3 of epithelial
malignancies in end-stage RCC fall into other diagnostic
categories. Acquired cystic disease associated RCC dem-
onstrate a morphologic spectrum of cribriform, micro-
cystic and sieve-like growth, with invariable deposits of
calcium oxalate crystals, which are characteristic. The
cells may show eosinophilic or clear cytoplasm and the
nucleoli are prominent. Cytokeratin 7 is typically nega-
tive. Most tumors show an indolent behavior.
Clear cell papillary RCC
Clear cell papillary RCC is probably the most common
type of the newly recognized entities. It is a low-grade
neoplasm composed by clear epithelial cells arranged in
tubules or papillae with a linear nuclear alignment away
from the basement membrane, with subnuclear vacuoles
(piano key appearance). These are indolent tumors that
should be distinguished from clear cell RCC. Strong
positivity for cytokeratin 7 is a useful tool, as well as
CAIX “cup-shaped” reactivity; CD10 is either negative or
only focally positive. The stroma may show variable
amounts of fibrous or smooth muscle bundles. Renal
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solete term for this renal tumor. Recent findings indicate
that this entity should not be overdiagnosed, because
there are cases with mixed features between clear cell
papillary RCC and clear cell conventional RCC (both
morphologic or by immunophenotype), and there are
other similar tumors, characterized by hotspot muta-
tions in TCEB1 [24, 25].Emerging renal entities
The ISUP 2012 renal tumor classification included a
category of emerging renal entities, acknowledging that
more data on morphology, immunophenotype and out-
come are needed for their formal recognition. This cat-
egory initially included thyroid-like follicular RCC, ALK
rearrangement-associated RCC and SDH-deficient RCC,
the latter now recognized as a new type by the WHO.
Other emerging tumors include RCC with angioleiomyo-
matous stroma, some of which show TCEB1 hotspot
mutations and may represent a distinct subtype [25],
while some examples are believed to be in the spectrum
of clear cell papillary RCC. A category of RCC in neuro-
blastoma survivors was removed from the 2016 WHO
classification, as some of these clearly belong to the
MiTF family translocation RCC, and some are difficult
to classify [26].
Eosinophilic, solid and cystic renal cell carcinoma
(ESC-RCC) is another emerging entity that has been de-
scribed recently. ESC-RCC occurs exclusively in female
patients with and without associated tuberous sclerosis
complex [27, 28]. Most tumors show mixed solid and
cystic gross appearance, and on microscopy they demon-
strate solid or compact nested growth of eosinophilic
cells admixed with cysts lined by with hobnailed cells. A
distinctive feature is the presence of coarse cytoplasmic
stippling (basophilic granules) and intracytoplasmic
globules. Immunostaining typically shows a cytokeratinFig. 5 a GCNIS is a proliferation of intratubular malignant germ cells with m
arising in the spermatogonial niche; note also the presence of intertubular
the tubules and in the interstitium20+, cytokeratin7—profile. These tumors demonstrate
indolent behavior.Grading of renal tumors
2016 WHO blue book recommended adoption of a
novel grading system called ISUP/WHO grading system
[29]. It simplifies and improves upon the previously
applied Fuhrman system, because it is based on the nu-
cleolar appearances and size, avoiding the requirement
of nuclear size estimation. ISUP/WHO is a four-tiered
grading system, defined as follows:
Grade 1: Inconspicuous or absent nucleoli at x400
magnification.
Grade 2: Nucleoli are conspicuous at x400x
magnification and visible but not prominent at x100
magnification.
Grade 3: Nucleoli are conspicuous at x100
magnification.
Grade 4: Extreme nuclear pleomorphism,
multinucleated giant cell and/or rabdoid/sarcomatoid
morphology.
To date, this system has been validated for clear cell
and papillary RCCs. This grading system should not be
applied to chromophobe RCC, and has not been vali-
dated for other less common tumor types.Testis
The 2016 WHO blue book recommended the term germ
cell neoplasia in-situ (GCNIS) to unify the terminology
of undifferentiated intratubular neoplasia, previously
known as carcinoma in-situ or intratubular germ cell
neoplasia, unclassified (IGCNU) (Fig. 5) [30]. Other vari-
ants of intratubular neoplasia demonstrating luminal
space-filling features should be designated with the pre-
fix intratubular, followed by the respective neoplasticorphologic and immunohistochemical features of seminoma cells
infiltrating seminoma. b IHC by C-kit (CD117) highlights the GCNIS in
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embryonal carcinoma). GCNIS is a proliferation of intra-
tubular malignant germ cells with morphologic and IHC
features of seminoma cells arising in the spermatogonial
niche. GCNIS should be distinguished from maturation-
delayed germ cells, which are common in patients with sex
development disorders, and are more diffusely distributed
and centrally located within seminiferous tubules, and lack
expression of KIT ligand (stem cell factor).
Germ cell tumors are now broadly separated into two
main groups: derived from GCNIS or unrelated to
GCNIS. Those derived from GCNIS share the features
of abnormal testicular development in the background,
such as impaired spermatogenesis, tubular atrophy, peri-
tubular sclerosis, interstitial expansion, and microlithia-
sis. These include: seminoma, embryonal carcinoma,
yolk sac tumor postpubertal type, trophoblastic tumors,
teratoma postpubertal type and teratoma with somatic-
type malignancy. Teratoma and yolk sac tumor may be-
long to both groups (related to or unrelated to GCNIS).
Thus, GCNIS-derived tumors are designated postpuber-
tal and those that are unrelated to CGNIS are labeled
prepubertal. The new classification also acknowledges
that the genetic backgrounds of teratoma and yolk sac
tumor are different in its pre- and postpuberal forms
and deserves separation into distinct entities. In additionFig. 6 a Clear cell carcinoma is a very rare penile carcinoma, which represents
demonstrates diffuse and strong staining for p16 on IHC. c Penile intraepithelia
changes with non-HPV related (differentiated) PeIN features. d Squamous cell c
focal squamous differentiation (keratohyaline pearl)to the presence or absence of GCNIS, prepubertal tera-
tomas and yolk sac tumors lack 12p amplification and
do not occur in malformed testes. Prepubertal teratoma
and yolk sac tumor, or mixed neoplasm composed by
both, share excellent prognosis [31]. Postpubertal tera-
toma comprises the previous “mature and immature
teratoma” categories and demonstrates a metastatic rate
of about 30%. The presence or quantification of the dys-
plastic or immature component does not need to be
specified if there are no expansive nodules larger than
one low power field (x 4 objective, 5 mm in diameter).
In addition to placental site trophoblastic tumor, the
genuine non-choriocarcinomatous trophoblastic tumors
now include epithelioid trophoblastic tumors and cystic
trophoblastic tumors. These are most common in meta-
static lesions or post-chemotherapy.
The tumors unrelated to GCNIS are a more heteroge-
neous group which include spermatocytic tumor (a new
term for spermatocytic seminoma), teratoma prepubertal
type (including dermoid cyst, epidermoid cyst and
monodermal teratoma—well differentiated neuroendo-
crine tumor), yolk sac tumor prepubertal type, and
mixed teratoma and yolk sac tumor, prepubertal type.
The low grade neuroendocrine tumor has a metastatic
rate that is lower than 15%. They may be pure (~70% of
all cases) or mixed with other teratoma components.an example of HPV-related penile carcinoma. b Clear cell carcinoma
l neoplasia (PeIN), a preneoplastic precursor lesion with dysplastic epithelial
arcinoma of penis, Grade 2, is comprised of poorly differentiated areas with
Athanazio and Trpkov Applied Cancer Research  (2016) 36:1 Page 10 of 11Minor changes are introduced in the sex cord-stromal
tumor category. Sclerosing Sertoli cell tumor is now in-
cluded in the Sertoli cell tumor, not otherwise specified,
due to the similar genetic background. However, it is
recommended that term sclerosing should still be used
to designate tumor containing more than 50% hipocellular
fibrous stroma, because these have a more favorable prog-
nosis. Intratubular large cell hyalinizing Sertoli tumor is a
new entity associated with Peutz-Jegers syndrome which
shows a characteristic mutation of STK1 gene. Gonado-
blastoma currently remains the sole entity in the mixed
germ cell–sex cord–stromal category. In the mesothelial
tumor section, the benign mesothelioma category was
abolished. Well differentiated papillary mesothelioma is
considered to be an indolent variant of mesothelioma.
The term cystic mesothelioma no longer exists and those
lesions should be considered either as non-neoplastic
mesothelial cysts or as variants of conventional
mesothelioma.
Penis
The previous penile classification was strictly morpho-
logical and the 2016 WHO classification, in addition to
the clinicopathologic features, takes into consideration
the relationship of the neoplasm to the human papilloma
virus (HPV) [32]. The great majority of penile malignant
tumors are squamous cell carcinomas (SCC), which are
now divided into two main groups, non-HPV related:
usual, pseudohyperplastic, pseudoglandular, verrucous—
with the cuniculatum variant, papillary, adenosquamous
and sarcomatoid) and HPV-related: basaloid and warty/
condilomatous, and other rare morphologies, such as
warty-basaloid, papillary-basaloid, clear cell (Fig. 6a-b),
lymphoepithelioma-like and medullary. Penile intraepithe-
lial neoplasia (PeIN), a preneoplastc precursor lesion
with dysplastic epithelial changes, is also grouped into
non-HPV related (differentiated PeIN) (Fig. 6c) and
HPV-related or undifferentiated (basaloid, warty or
basaloid-warty) type [33]. A three tiered WHO/ISUP
grading system is now recommended for SCC: Well-
differentiated SCC, Grade 1, with cytological features of
normal squamous epithelium, growing in large sheets
or irregular nests with little intervening stroma; Grade
2 SCC, comprised of cases showing intermediate fea-
tures between Grade 1 and 3 (Fig. 6d); and poorly dif-
ferentiated carcinoma, Grade 3, showing smaller tumor
nests with poor keratinization and difficult to find
pearls, irregular infiltrative and polymorphic growth,
frequent mitoses and marked stromal reaction.
Conclusions
The 2016 World Health Organization (WHO) Classifi-
cation of Tumors of the Urinary System and Male
Genital Organs reflects an improved understanding andknowledge of the morphologic types and variants of
urologic tumors. It also provides novel insights in the
molecular and genetic background and biological be-
havior of the genitourinary neoplasms. It is anticipated
that the adoption of the new diagnostic categories and
grading systems will increase the diagnostic reproduci-
bility and clinicopathological correlation and prognosti-
cation, leading to a better patient care worldwide.
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